Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

In recent years, there has been a significant increase in the number of patients with malignancies treated with immune checkpoint inhibitors (ICIs), including the anti-programmed cell death protein 1 (anti–PD-1) agent pembrolizumab. One of the important aspects of conducting clinical trials with ICI...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. Yu. Fedyanin, A. V. Snegovoy, V. V. Breder, Yu. N. Linkova, A. V. Zinkina-Orikhan, S. B. Setkina, S. N. Fogt, V. S. Chistiakov, N. A. Kravtsova
Format:	Article
Language:	Russian
Published:	Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2023-06-01
Series:	Безопасность и риск фармакотерапии
Subjects:	pembroria pembrolizumab biosimilar pd-1 inhibitor immune-related adverse events immune-mediated adverse reactions immune-checkpoint inhibitors immunotherapy clinical trials
Online Access:	https://www.risksafety.ru/jour/article/view/360
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

Similar Items